2 May 2016 - No sighificant differences for moderate disease and no data for severe disease.

Umeclidinium bromide has been approved since 2014 as a maintenance bronchodilator treatment in adults with chronic obstructive pulmonary disease (COPD) and was initially only available in combination with vilanterol trifenatate. It has been available also as a single agent since 2016. The German IQWiG now examined in an early benefit assessment whether this single agent offers patients an added benefit over the appropriate comparator therapy.

As in 2015 for the combination therapy, the Institute concluded that an added benefit in comparison with the appropriate comparator therapy is not proven for umeclidinium bromide.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/umeclidinium-for-symptom-relief-in-copd-added-benefit-not-proven.7316.html